MetXtra™ technology platform: overcoming the limits of industrial biocatalysis
The MetXtra™ technology platform opens up new possibilities for producing special and highly efficient enzymes.
With MetXtra™, BRAIN Biotech has created a comprehensive technology platform that enables innovative solutions for biocatalysis. The platform was developed by BRAIN Biotech specifically for new and improved enzyme processes to overcome the current limitations of industrial biocatalysis.
Creating competitive advantages by intelligently combining nature with bioinformatics and AI
MetXtra™ combines natural diversity with state-of-the-art bioinformatics and artificial intelligence to provide superior enzymes with high efficacy. Unique enzymes can be identified in BRAIN Biotech’s proprietary database of unexplored, Nagoya-compliant, novel sequences resulting from the fusion of the metagenomic sequence databases of BRAIN Biotech AG and Biocatalysts Ltd. The discovery of enzymes is tailored to the desired application utilizing BRAIN Biotech´s broad sequence and structural bioinformatics and AI toolbox. Additionally, new enzymes outside the natural sequence space are designed via artificial intelligence.
![]()
MetXtra gives our customers access to a comprehensive database of previously undiscovered enzymes. The cutting-edge bioinformatics methods allow us to quickly and precisely identify the appropriate enzyme for their specific applications, giving them a significant competitive advantage.
- VP, Head of Research and Development at BRAIN Biotech Zwingenberg
Development and production of novel enzymes in the BRAIN Biotech Group
BRAIN Biotech offers customers access to the MetXtra™ technology platform if they want to establish and optimize biocatalytic processes, develop novel enzyme solutions and generate IP or FTO.
MetXtra™ is fully integrated into the BRAIN Biotech Group's enzyme development pipeline. This offers excellent enzyme engineering capabilities, access to industrial enzyme production strains and scale-up technologies. In this way, the group enables enzyme solutions from discovery to commercial production.